Figure 1.

Change in forced vital capacity (FVC) % predicted (% pred) per week from baseline in the CAPACITY 004 and 006 study comparing pirfenidone (2403 mg·day⁻¹) or placebo in patients with idiopathic pulmonary fibrosis (IPF). CAPACITY: Clinical Studies Assessing Pirfenidone in IPF: Research of Efficacy and Safety Outcomes. Reproduced from [23].